Taiwan
· Delayed Price · Currency is TWD Ever Supreme Bio Technology Statistics
Total Valuation
Ever Supreme Bio Technology has a market cap or net worth of TWD 14.20 billion. The enterprise value is 13.57 billion.
| Market Cap | 14.20B |
| Enterprise Value | 13.57B |
Important Dates
The last earnings date was Tuesday, November 5, 2024.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | May 29, 2024 |
Share Statistics
Ever Supreme Bio Technology has 80.67 million shares outstanding. The number of shares has decreased by -1.60% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 80.67M |
| Shares Change (YoY) | -1.60% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 3.49% |
| Owned by Institutions (%) | 2.94% |
| Float | 57.89M |
Valuation Ratios
The trailing PE ratio is 55.91.
| PE Ratio | 55.91 |
| Forward PE | n/a |
| PS Ratio | 16.81 |
| PB Ratio | 8.97 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 34.50 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 33.18, with an EV/FCF ratio of 32.96.
| EV / Earnings | 53.34 |
| EV / Sales | 16.06 |
| EV / EBITDA | 33.18 |
| EV / EBIT | 35.82 |
| EV / FCF | 32.96 |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.00.
| Current Ratio | 3.31 |
| Quick Ratio | 2.90 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 2,669.23 |
Financial Efficiency
Return on equity (ROE) is 15.29% and return on invested capital (ROIC) is 14.18%.
| Return on Equity (ROE) | 15.29% |
| Return on Assets (ROA) | 12.40% |
| Return on Capital (ROIC) | 14.18% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.44 |
| Inventory Turnover | 2.75 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.56% in the last 52 weeks. The beta is 0.28, so Ever Supreme Bio Technology's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -1.56% |
| 50-Day Moving Average | 181.14 |
| 200-Day Moving Average | 187.23 |
| Relative Strength Index (RSI) | 37.18 |
| Average Volume (20 Days) | 199,547 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ever Supreme Bio Technology had revenue of TWD 844.86 million and earned 254.33 million in profits. Earnings per share was 3.15.
| Revenue | 844.86M |
| Gross Profit | 591.48M |
| Operating Income | 379.03M |
| Pretax Income | 334.82M |
| Net Income | 254.33M |
| EBITDA | 397.31M |
| EBIT | 379.03M |
| Earnings Per Share (EPS) | 3.15 |
Balance Sheet
The company has 638.43 million in cash and 5.70 million in debt, giving a net cash position of 632.74 million or 7.84 per share.
| Cash & Cash Equivalents | 638.43M |
| Total Debt | 5.70M |
| Net Cash | 632.74M |
| Net Cash Per Share | 7.84 |
| Equity (Book Value) | 1.58B |
| Book Value Per Share | 19.63 |
| Working Capital | 635.97M |
Cash Flow
In the last 12 months, operating cash flow was 416.91 million and capital expenditures -5.31 million, giving a free cash flow of 411.60 million.
| Operating Cash Flow | 416.91M |
| Capital Expenditures | -5.31M |
| Free Cash Flow | 411.60M |
| FCF Per Share | 5.10 |
Margins
Gross margin is 70.01%, with operating and profit margins of 44.86% and 30.10%.
| Gross Margin | 70.01% |
| Operating Margin | 44.86% |
| Pretax Margin | 39.63% |
| Profit Margin | 30.10% |
| EBITDA Margin | 47.03% |
| EBIT Margin | 44.86% |
| FCF Margin | 48.72% |
Dividends & Yields
This stock pays an annual dividend of 5.45, which amounts to a dividend yield of 3.11%.
| Dividend Per Share | 5.45 |
| Dividend Yield | 3.11% |
| Dividend Growth (YoY) | 231.16% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 173.02% |
| Buyback Yield | 1.60% |
| Shareholder Yield | 4.71% |
| Earnings Yield | 1.79% |
| FCF Yield | 2.90% |
Stock Splits
The last stock split was on May 29, 2024. It was a forward split with a ratio of 1.1000011.
| Last Split Date | May 29, 2024 |
| Split Type | Forward |
| Split Ratio | 1.1000011 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |